公开(公告)号：US11261482B2

公开(公告)日：2022-03-01

申请号：US16304340

申请日：2017-05-25

Applicant: GENCURIX INC.

Inventor： Young Kee Shin ,  Bohyun Byun ,  Hyunjeung Choi ,  Joon Seok Choi ,  Young Ho Moon ,  Jong Heun Lee ,  Sang Rea Cho ,  Jee Eun Kim ,  Myungsun Kim

IPC: C12Q1/68 ,  C07H21/04 ,  C12Q1/6827 ,  C12Q1/6823 ,  C12Q1/686 ,  C12Q1/6874 ,  C12Q1/6886

Abstract: The present invention relates to a composition for detecting an epidermal cell growth factor receptor gene mutation and to a kit comprising the composition and, more specifically, to a primer and probe set composition for detecting an epidermal cell growth factor gene mutation, and to a kit for detecting an EGFR gene mutation, comprising the composition. A method according to the present invention can not only predict and diagnose responsiveness to a therapeutic agent for the prognosis of a cancer patient, but also predict a cancer metastasis or relapse Thus, the method can be useful for the purposes of determining the need to administer an anticancer therapeutic agent and guiding the direction of future treatment, and for monitoring a cancer metastasis or relapse.

公开(公告)号：US20160102359A1

公开(公告)日：2016-04-14

申请号：US14886948

申请日：2015-10-19

Applicant: GENCURIX INC.

Inventor： Young Kee SHIN ,  Young-Deug Kim ,  En Sel Oh ,  Jun Young Choi ,  Sang Rea Cho

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N2800/52

Abstract: A gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof is disclosed, and more specifically a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3 member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.

Abstract translation: 公开了一种用于预测或诊断早期乳腺癌预后的基因及其用途，更具体地，涉及用于预测或诊断乳腺癌预后的遗传标记，包括TRBC1（T细胞受体β常数1），BTN3A2 （雌激素，亚家族3成员A2）或HLA-DPA1（主要组织相容性复合物，II类，DPα1），用于提供预测或诊断乳腺癌患者预后所需的信息。 遗传标记允许预测或诊断乳腺癌患者的预后，因此可以有利地用于为乳腺癌治疗的未来方向提供方向，包括是否需要抗癌治疗的决定。

公开(公告)号：US10655187B2

公开(公告)日：2020-05-19

申请号：US16155220

申请日：2018-10-09

Applicant: GENCURIX INC.

Inventor： Young Kee Shin ,  Young-Deug Kim ,  En Sel Oh ,  Jun Young Choi ,  Sang Rea Cho

IPC: C07H21/04 ,  C12Q1/68 ,  C12Q1/6886

Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.